Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-2218 in healthy volunteers and chronic hepatitis B
NCT03672188Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Nov 2018
- Primary completion
- Sep 2020
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
A Phase 2 trial of elebsiran in Chronic Hepatitis B (CHB), sponsored by Vir Biotechnology. Started Nov 2018; status: completed.
02
Drugs
elebsiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03672188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672188.